

NON-HFE IRON OVERLOAD: IS PHLEBOTOMY THE ANSWER?

S. Hazeldine¹, D. Trinder^{2,3}, J. K. Olynyk^{1,2,4,5}

Affiliations:

1. Department of Gastroenterology, Fremantle Hospital, Fremantle, Western Australia.
2. School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia.
3. Western Australian Institute for Medical Research, Fremantle Hospital, Fremantle, Western Australia.
4. Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia.
5. Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, Western Australia.

Email Addresses:

s.hazeldine@doctors.org.uk

debbie.trinder@uwa.edu.au

john.olynyk@health.wa.gov.au

Corresponding Author:

John K. Olynyk

PO Box 480, Fremantle, Western Australia, 6959

Tel: +618 94312480

Fax: +618 94312340

Financial support:

JKO is the recipient of a NHMRC Practitioner Fellowship (513761). DT is the recipient of a NHMRC Senior Research Fellowship (1020437).

Abstract

Iron is an essential factor for life, however a physiologically optimal balance is critical. In this article we explore the role of iron as a co-factor in a range of chronic liver diseases and how it may contribute to the development of liver injury, fibrosis, cirrhosis and ultimately hepatocellular carcinoma. Whilst iron depletion therapy through phlebotomy is the most effective method of reducing iron stores, it is unclear whether this offers utility in the therapy of liver diseases in which iron is not the primary insult resulting in tissue injury. Here we examine the emerging evidence in the field of non-HFE hereditary haemochromatosis conditions associated with iron overload – is phlebotomy the answer?

Keywords ferritin; iron; phlebotomy; hepcidin; non-alcoholic fatty liver disease; hepatitis C; porphyria cutnea tarda; alcoholic liver disease; metabolic syndrome.

Introduction

Iron (Fe) is an essential factor for life, however a physiologically optimal balance is critical. Too much or too little iron can have detrimental effects on human health. Evidence for the part that Fe plays in hepatic and extrahepatic diseases is fast gathering pace. In this article we explore the role of Fe as a co-factor in a range of chronic liver diseases and how it may contribute to the development of liver injury, fibrosis, cirrhosis and ultimately hepatocellular carcinoma (HCC). Fe depletion through therapeutic phlebotomy is the most effective method of reducing body Fe stores, however it is unclear whether this offers utility in the therapy of liver diseases in which Fe is not the primary insult.

Regulation of iron metabolism in health and disease

In healthy individuals approximately 1-2 mg of Fe is absorbed from the diet per day to maintain Fe balance. Once absorbed, the Fe is bound by the plasma protein transferrin and is transported to the tissues where most of the Fe is taken up by the bone marrow for incorporation into haemoglobin for erythropoiesis, and to a lesser degree by the muscle for the synthesis of myoglobin and respiratory enzymes. The excess Fe is stored primarily in the liver. Macrophages degrade the erythrocyte-derived haemoglobin and release the Fe back into the plasma, so it can be re-utilised for erythropoiesis in the bone marrow. Too much Fe is detrimental to health as excess Fe generates free radicals causing oxidative stress and tissue damage primarily in the liver, heart and pancreas [1-3]. Providing further evidence as to the detrimental effects of Fe, it has now been shown that reduction of body Fe stores by phlebotomy therapy, even within the normal physiological range, is associated with reduced mortality from endpoints such as cancer [4].

Fe metabolism is tightly regulated by the Fe-regulatory hormone hepcidin, which is highly expressed by hepatocytes and at lower levels in other tissues including the kidneys. Hepcidin is a negative regulator of Fe absorption by the intestine, Fe release from macrophages and hepatic stores. It is secreted into the circulation and binds to the Fe exporter ferroportin, which is expressed on the surface of enterocytes, macrophages and hepatocytes, causing ferroportin internalisation and degradation. This limits the absorption and release of Fe and increases retention in the liver and macrophages [1, 5]. Hepcidin expression is influenced by the balance of a number of positive and negative regulators (Fig. 1). Excess Fe, inflammation and endoplasmic reticulum stress up-regulate hepcidin expression, which in turn, limits the availability of Fe for erythropoiesis and other Fe-dependent processes. Fe deficiency, erythropoiesis and reactive oxygen species (ROS) down-regulate hepcidin expression, which subsequently increases Fe bioavailability. Fe dependent regulation of hepcidin is controlled by bone morphogenetic protein /haemojuvelin/SMAD and HFE/transferrin receptor 2 (TFR2) signalling pathways. The pro-inflammatory cytokine interleukin-6 (IL-6) upregulates liver hepcidin via a STAT3 signalling pathway [1, 2]. During anaemia increased erythropoietic activity is required to down-regulate hepcidin expression and this is regulated by a number of factors including growth differentiation factor 15, while hypoxia and erythropoietin can also directly impair hepcidin expression. ROS reduces hepcidin via CCAAT/enhancer-binding protein α (C/EBP α) signalling pathway [1, 2].

Diagnosis of iron overload and tissue injury

Fe overload can be suspected from clinical information or elevated serum Fe biochemistry, but definitive diagnosis requires measurement of body Fe content (reviewed in [2]). This can be achieved by MRI-based R2 relaxometry, liver biopsy measurement of hepatic Fe concentration (HIC), or quantitative venesection [2, 6, 7]. Clinical features are nonspecific [2, 6, 7] whilst a history of transfusion or administration of Fe (oral or intravenous) can be used to provide an estimate for the dose of administered Fe [8]

Serum measures of Fe biochemistry (transferrin saturation (TSAT) and serum ferritin) are well established in assessment of Fe overload in Hereditary Haemochromatosis (HH) and transfusion-related Fe overload. Unfortunately, measurements of serum ferritin may not accurately reflect the amount of Fe in the body because factors including body mass index, infection, inflammatory diseases or malignancy can also alter ferritin levels [1, 6, 9].

The most objective parameter of Fe overload is direct measurement of organ Fe concentration. Measurement of HIC accurately reflects total body Fe stores. Liver biopsy provides quantitative measurement of HIC and liver pathology, but it is invasive and subject to sampling error [10]. The most accurate non-invasive methods use magnetic resonance imaging [2, 11, 12]. A validated non-invasive MRI-based R2 relaxometry method has been described which accurately measures hepatic (HIC, FerriScan[®]) and cardiac ($T2^*/R2^*$) Fe concentration in a range of diseases [11, 13]. Once a certain threshold of HIC is exceeded, Fe can begin to accumulate in the heart and other organs [14]. HICs above 130 $\mu\text{mol/g}$ dry weight are associated with increased risks of liver injury [15] whilst clinical cardiac toxicity occurs when HIC exceeds 270 $\mu\text{mol/g}$ [16]. Changes in HIC generally precede changes in cardiac Fe

loading [14], acting as an early warning of possible future cardiac complications. Direct measurement of cardiac Fe deposition using the T2*/R2* MRI method enables assessment of the risk of Fe-induced arrhythmia and cardiac failure [13], and correlates with new echocardiographic measures using 2D speckle tracking [17].

Tissue injury can also be ascertained using non-invasive approaches. An increasing number of blood tests that estimate the likelihood of significant liver fibrosis or cirrhosis have been introduced. Most have been validated in chronic viral hepatitis and non-alcoholic fatty liver disease (NAFLD) [18, 19]. There have been various serum biomarkers suggested for use in Fe overload states, namely AST, platelets and ferritin [20, 21]. Transient elastography (FibroScan) is a non-invasive measure of liver 'stiffness' that gives an accurate indication of the presence of fibrosis [22]. It is a relatively simple, reproducible bedside test. Stebbing et al performed a meta-analysis and showed that a liver stiffness of 7.71 kPa for fibrosis (F2 or greater) had a sensitivity of 71.9% and specificity of 82.4% whereas for cirrhosis (F4) the results showed a cutoff of 15.08 kPa with a sensitivity of 84.45% and specificity of 94.69% [23]. Limitations include obesity and active inflammation, which can give falsely high results. Despite the good predictive values for cirrhosis, FibroScan scores do not correlate with serum ferritin levels in Hereditary Haemochromatosis (>7.1kPa) [24]. A longitudinal study in transfusion-independent β -thalassaemia patients showed correlation between serum ferritin levels and liver stiffness over 4 years [25].

Mechanism of iron-induced liver injury

An increase in hepatic Fe stores is linked to more severe fibrosis in alcoholic liver disease, non-alcoholic steatohepatitis (NASH) and viral hepatitis but not biliary causes of liver disease [26, 27]. In well-compensated cirrhosis, the presence of

stainable Fe on liver biopsy may be predictive of more rapid deterioration in liver function compared with patients without siderosis [28]. An excess of hepatocellular Fe generates ROS that cause lysosomal fragility [29], mitochondrial dysfunction [30] via lipid peroxidation of organelle membranes, resulting in the formation of protein and DNA adducts and mutation [31]. Usual cellular protective mechanisms are overwhelmed in Fe overload states leading to apoptosis and cell necrosis.

Hepatic stellate cells (HSCs) play a pivotal role in the production of extracellular collagen and connective tissue matrix resulting in hepatic fibrosis. When this occurs concurrently with dysregulated regeneration, cirrhosis and HCC may ensue [32]. HSCs are activated, in part, by oxidative stress due to Fe loading and a direct link between Fe and fibrogenesis via HSC activation has been demonstrated [33]. Liver progenitor cells (LPCs) are involved in hepatic regeneration during chronic liver injury [34], where their numbers are strongly correlated with disease severity [35]. LPCs are found in close proximity to HSCs and exhibit cellular cross-talk via a paracrine signalling mechanism [36]. LPCs are often observed in liver diseases associated with Fe overloading including HH, alcohol-related liver disease, chronic hepatitis B and C infection [35, 37, 38], non alcoholic fatty liver disease [39]. Dietary Fe loading of rats has also been shown to induce proliferation of LPCs [40].

Definition of Fe overload disorders

Fe overload exists when tissue or body Fe stores are elevated above the normal range. Such elevations can occur in a range of primary or secondary Fe overload disorders (table 1). Primary (or genetic) aetiologies are reviewed extensively elsewhere [2]. For the remainder of this article we will focus on the role of iron as a secondary factor in a range of common liver diseases and malignancy.

Chronic Hepatitis C

Elevated serum iron parameters in patients with chronic hepatitis C are present in up to 36% of patients [41]. Patients with chronic hepatitis C have higher levels of steatosis, serum ferritin, TSAT and tissue Fe compared with other forms of chronic liver disease. The role of hepcidin in chronic hepatitis C remains unclear. Hepcidin levels may either be decreased in response to elevated levels of ROS or up-regulated due to inflammation and endoplasmic reticulum stress [42]. Fe contributes to the increased risk of hepatocellular carcinoma through DNA damage from Fe-induced adduct formation and chromosomal damage [43, 44]. In addition, hepatitis C virus may have a direct cytopathic effect on hepatocytes through the occurrence of Fe-dependent lipid peroxidation [45]. Individuals heterozygous for C282Y or H63D mutations in the *HFE* gene product in conjunction with chronic hepatitis C are at increased risk of developing hepatocyte damage and liver fibrosis [46]. Fe has been shown in many studies to impair immune responses and potentially lymphocyte-dependent clearance of the hepatitis C virus [47, 48]

Following the introduction of interferon monotherapy, lower levels of stainable Fe were shown to be associated with a better response to interferon alpha therapy [49] and treatment resulted in a reduction in HIC [50]. Later studies suggested that an HIC of greater than 1100 $\mu\text{g Fe /g}$ was predictive of non-response in nearly 90% of patients [51, 52] and increased serum and/or hepatic Fe parameters were associated with a lower likelihood of response to interferon therapy [53]. However, following the introduction of combination interferon and ribavirin therapy, the presence of raised HIC no longer influenced the likelihood of a sustained virological response rate when treating patients [54]. Interestingly, elevated serum ferritin levels

remained a predictor of response to pegylated interferon and ribavirin and were also associated with more severe liver fibrosis [55]. A significant rise in serum ferritin levels during the initial weeks of treatment has been associated with a good treatment response; this is likely to reflect a higher level of inflammation during this phase [56]. More recently, Ryan et al [57] showed that following initiation of pegylated interferon alpha and ribavirin therapy there was a significant increase in serum hepcidin levels and hypoferraemia (a reduced serum iron concentration and TSAT). The level of hypoferritnaemia was most marked in those with a most substantial decline in viral load, a well-known predictor of an increased likelihood of sustained viral response [58]. Thus changes in Fe metabolism, or effects of altered hepcidin levels directly, which is known to have an effect on the immune system, could play a significant role in chronic hepatitis C infection and possible success of therapy.

When therapeutic phlebotomy was trialed in patients with chronic hepatitis C it was initially shown to reduce serum alanine aminotransferase (ALT) [59], improvement in liver histology [60, 61] and lower the risk of HCC development [62]. Phlebotomy prior to therapy with interferon- α was variably shown to improve the likelihood of sustained virological response in some studies [59, 63] but not others [60, 61]. Fe depletion therapy has not been shown to effect hepatitis C virus levels [59]. More recently Gentile et al. showed that venesection to a serum ferritin <50ng/ml did not improve the outcome of pegylated interferon based therapy [64]. Not only has phlebotomy therapy not been evaluated either prior to or during modern combination therapy containing ribavirin, it would be extremely difficult given the common complication of anaemia due to such therapy. At present Fe-depletion therapy cannot be recommended for treatment of chronic hepatitis C infection.

Alcohol-related liver disease

Excessive alcohol consumption causes liver disease including steatosis, alcoholic hepatitis, cirrhosis and HCC. The amount of alcohol consumed does not have a direct correlation to the severity of the liver disease [65], suggesting that there are genetic and environmental factors influencing disease progression. It is possible that Fe could represent such an environmental factor. Alcoholic liver disease is often associated with elevated serum ferritin levels [66] and studies have suggested that it is the increased presence of Fe that acts synergistically with alcohol to cause increased rates of fibrosis [67, 68]. Alcohol induced hyperferritinaemia is most likely due to hepatocyte damage and induction of ferritin synthesis by pro-inflammatory cytokines [68]. Alcohol consumption leads to increased hepatocyte Fe uptake from desialylated transferrin in patients with ALD [69]. Alcohol and Fe induce oxidative stress which inhibits hepatic hepcidin production, resulting in increased Fe absorption and deposition in the liver [42].

A higher level of alcohol consumption in HH patients with HFE C282Y homozygosity leads to an increased rate of cirrhosis [70]. Animal studies have confirmed that in setting of alcohol excess, diet-induced Fe overload leads to an increase in oxidative stress in the liver and the development of liver fibrosis and cirrhosis [67, 68]. Conversely, Fe depleted diets lead to a reduction of alcohol induced liver disease [69]. It is the synergistic effects of alcohol and Fe on oxidative stress levels that accelerates an individual's progression to fibrosis and cirrhosis

To date, there have been no studies addressing the therapeutic utility of phlebotomy therapy in chronic alcoholic liver disease and thus no recommendation can be made regarding the use of phlebotomy treatment in this condition.

Non-alcoholic fatty liver disease (NAFLD)

NAFLD is a common cause liver disease and is becoming increasingly prevalent. Deposition of lipids causes the liver to be more vulnerable to damage from other stresses including hormones derived from adipose tissue (adipocytokines), oxidative stress and intestine-derived bacterial endotoxin [71]. Steatohepatitis is associated with nuclear factor kappa B and c-Jun N terminal kinase-mediated production of hepatic inflammatory cytokines such as tumour necrosis factor and interleukin (IL) 6, resulting in elevated serum aminotransferase levels and hepatomegaly [72, 73]. In NAFLD, hepcidin levels are affected by a variety of factors: increased iron stores, endoplasmic reticulum stress and inflammation via IL-6 increase hepcidin production, whereas oxidative stress leads to a decrease in hepcidin levels [74]. It is likely to be the combination of hepatic steatosis and an additional insult (Fe or alcohol) that initiates the oxidative stress cascade of lipid peroxidation, mitochondrial dysfunction, inflammation, apoptosis [71].

Ferritin levels are increased in 20-60% patients with NAFLD, but despite this only 5-10% patients have evidence of hepatic Fe overload [75]. Hyperferritinaemia in NAFLD usually reflects hepatic inflammation and fibrosis rather than true Fe overload. Kowdley et al. showed that a serum ferritin greater than 1.5 times upper limit upper limit of normal in patients with NAFLD is an independent predictor of advanced hepatic fibrosis [76]. Hepatic Fe overload in patients with non-alcoholic steatohepatitis-related cirrhosis is observed more commonly in those patients that develop HCC than those who do not [77].

Fe-depletion therapy in patients with NAFLD, (even with normal body Fe stores) can result in the near normalisation of serum ALT levels and marked improvements in insulin sensitivity and improves insulin resistance [78]. Despite this,

it is generally thought that hepatic Fe overload does not play a major role in liver damage in those patients with NAFLD [79]. To date, phlebotomy has not been shown to have a significant impact in histological or clinical outcomes in NAFLD.

Porphyria cutanea tarda (PCT)

PCT is due to an acquired deficiency of hepatic uroporphyrinogen decarboxylase (UROD) and characterised by skin and liver involvement caused by porphyrin accumulation. Many factors contribute to the susceptibility of an individual acquiring clinically detectable PCT including hepatitis C virus infection, alcohol consumption, smoking, Human Immunodeficiency Virus infection, oestrogens and end stage renal failure. The above factors are capable of causing oxidative stress within the liver, potentially reducing hepcidin production thus increasing Fe absorption from the intestine and Fe release from macrophage stores, increasing serum iron levels and HIC [80]. Although hepatic Fe deposition in PCT is usually mild to moderate, it may promote the oxidation of porphyrinogens, leading to the crystallisation of porphyrins [81].

Fe deficiency protects individuals from reduced UROD activity [82] and it has been long established that venesection, to decrease the Fe load in the liver, in almost all cases leads to remission [83]. The therapeutic aim is to reduce ferritin to below <25ng/mL [84, 85]. Maintenance of low serum ferritin levels will prevent recurrence of the condition [86]

Metabolic syndrome, cardiovascular disease and cancer

The metabolic syndrome (METS) includes abdominal obesity, dyslipidaemia, insulin resistance, glucose intolerance and hypertension. Increased Fe stores have

been postulated to play a role in pathogenesis of insulin resistance by increasing oxidative stress [87]. Patients with type 2 diabetes often have hyperferritinaemia due to the inflammation, insulin resistance and steatosis often associated with type 2 diabetes [88]. A reduction of ferritin levels in rats with type 2 diabetes via either phlebotomy or dietary Fe-restriction leads to an improvement in HbA1c levels [89]. In a study in which patients with METS were randomly assigned to Fe reduction therapy with phlebotomy, reduction of ferritin by two sessions of phlebotomy resulted in a reduction of systolic blood pressure, improvements in markers of cardiovascular risk and glycemic control [90]. Multiple studies now demonstrate that Fe depletion therapy can reduce HbA1c levels, increase insulin release and sensitivity. A recent review article has addressed the issue of Fe and metabolic syndrome in depth [91].

In patients with steatosis, increased Fe stores have been linked to a faster progression to cardiovascular disease [92]. Increased serum ferritin has been shown to be an independent risk factor for the presence of coronary artery calcium [93] although there is no evidence from population studies that ferritin is a risk factor for cardiovascular disease [94]. There is also no evidence that HFE gene mutations are associated with an increased risk of cardiovascular disease [95]. Moreover, mortality from cardiovascular disease is not associated with raised serum ferritin levels [96]. A large randomised clinical study of phlebotomy therapy in US veterans failed to demonstrate any risk reduction of cardiovascular events through phlebotomy therapy [4].

Fe has also been implicated as a factor which may increase the risk of cancer. The role of Fe in HCC development is well-documented and hepatic Fe overload, whether due to primary or secondary disorders of iron overload, is associated with an increased risk of HCC. The development of HCC is due to DNA damage related to Fe

toxicity, impaired liver regeneration and the wound-healing response, LPC proliferation and the evolution of cancer stem cells [97, 98]. It has also been demonstrated that patients with HFE C282Y homozygosity have a three-fold increase in the risk of colorectal cancer and breast cancer [99] and blood donation has been shown to be associated with lower cancer risk [100]. Zarcharski et al showed that in a predominantly older male population with peripheral vascular disease that Fe reduction therapy with venesection to a ferritin target range from 12-60 ng/ml resulted in a significant reduction of new visceral malignancies over a follow up period of 4.5 years [4]. Whilst these studies are encouraging, there is currently no consensus supporting a recommendation that blood donation should be advocated to reduce the risk of cancer *per se*.

Conclusion

Hepatic Fe is an important cofactor producing liver injury through the induction of oxidative stress, cellular damage and altered hepcidin production. Hepatic Fe deposition may contribute to increased fibrosis, cirrhosis and HCC. Phlebotomy therapy to reduce hepatic Fe stores and serum ferritin has only been shown to be of benefit in Hereditary Haemochromatosis and PCT. Hepatic Fe clearly has a synergistic affect on fibrosis and cirrhosis when due to alcohol, chronic hepatitis C or NAFLD. Evidence for a role of Fe in hepatic and extrahepatic diseases continues to accumulate and approaches to modulate Fe bioavailability or reduce body stores through phlebotomy may eventually become attractive therapeutic options.

References

1. Chua AC, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. *Critical Reviews in Clinical Laboratory Sciences*. 2007;44:413-459.
2. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR: Hereditary hemochromatosis in the post-HFE era. *Hepatology* 2008, 48:991-1001.
3. Beutler E, Hoffbrand AV, Cook JD: Iron deficiency and overload. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program* 2003:40-61.
4. Zacharski LR, Chow BK, Howes PS et al.: Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. *Journal of the National Cancer Institute* 2008, 100:996-1002.
5. Graham RM, Chua AC, Herbison CE, Olynyk JK, Trinder D: Liver iron transport. *World Journal of Gastroenterology* 2007, 13:4725-4736.
6. Siah CW, Trinder D, Olynyk JK: Iron overload. *Clinica chimica acta; International Journal of Clinical Chemistry* 2005, 358:24-36.
7. Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK: Clinical perspectives on hereditary hemochromatosis. *Critical Reviews in Clinical Laboratory Sciences* 2008, 45:451-484.
8. Siddique A, Kowdley KV: Review article: the iron overload syndromes. *Alimentary Pharmacology & Therapeutics* 2012, 35:876-893.
- 9. Olynyk JK, Gan E, Tan T: Predicting iron overload in hyperferritinemia. *Clinical Gastroenterology and Hepatology* 2009, 7:359-362.
This study showed that in individuals with hyperferritinaemia if there is no HFE gene mutation then the person is very unlikely to have significant hepatic iron loading (greater than 3 times normal).
10. Abdi W, Millan JC, Mezey E: Sampling variability on percutaneous liver biopsy. *Archives of Internal Medicine* 1979, 139:667-669.
11. St Pierre TG, Clark PR, Chua-anusorn W et al: Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. *Blood* 2005, 105:855-861.
12. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR: Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. *The American Journal of Gastroenterology* 2005, 100:837-841.
13. Kirk P, Roughton M, Porter JB et al: Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. *Circulation* 2009, 120:1961-1968.
14. Jensen PD, Jensen FT, Christensen T et al.: Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferoxamine: indication of close relation between myocardial iron content and chelatable iron pool. *Blood* 2003, 101:4632-4639.
15. Cartwright GE, Edwards CQ, Kravitz K et al.: Hereditary hemochromatosis. Phenotypic expression of the disease. *The New England Journal of Medicine* 1979, 301:175-179.
16. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. *Blood* 1997, 89:739-761.

17. Cheung YF, Liang XC, Chan GC, Wong SJ, Ha SY: Myocardial deformation in patients with Beta-thalassemia major: a speckle tracking echocardiographic study. *Echocardiography* 2010, 27:253-259.
18. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut* 2010, 59:1265-1269.
19. Adams LA, Bulsara M, Rossi E et al.: Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. *Clinical Chemistry* 2005, 51:1867-1873.
20. Beaton M, Guyader D, Deugnier Y et al.: Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. *Hepatology* 2002, 36:673-678.
21. Castiella A, Zapata E, Otazua P et al.: [Utility of various non-invasive methods for fibrosis prediction among Basque Country patients with phenotypic hemochromatosis]. *Revista Espanola de Enfermedades Digestivas : Organo Oficial de la Sociedad Espanola de Patologia Digestiva* 2008, 100:611-614.
22. Castera L, Forns X, Alberti A: Non-invasive evaluation of liver fibrosis using transient elastography. *Journal of Hepatology* 2008, 48:835-847.
23. Stebbing J, Farouk L, Panos G et al.: A meta-analysis of transient elastography for the detection of hepatic fibrosis. *Journal of Clinical Gastroenterology* 2010, 44:214-219.
24. Adhoute X, Foucher J, Laharie D et al.: Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. *Gastroenterologie Clinique et Biologique* 2008, 32:180-187.
25. Musallam KM, Motta I, Salvatori M et al.: Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with beta-thalassemia intermedia. *Blood Cells, Molecules & Diseases* 2012, 49:136-139.
26. Raynard B, Balian A, Fallik D et al.: Risk factors of fibrosis in alcohol-induced liver disease. *Hepatology* 2002, 35:635-638.
27. Hezode C, Cazeneuve C, Coue O et al.: Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. *Journal of Hepatology* 1999, 31:979-984.
28. Kayali Z, Rangelov R, Mitros F et al.: Hemosiderosis is associated with accelerated decompensation and decreased survival in patients with cirrhosis. *Liver International : Official Journal of the International Association for the Study of the Liver* 2005, 25:41-48.
29. O'Connell MJ, Ward RJ, Baum H, Peters TJ: The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes. *The Biochemical Journal* 1985, 229:135-139.
30. Bacon BR, O'Neill R, Park CH: Iron-induced peroxidative injury to isolated rat hepatic mitochondria. *Journal of Free radicals in Biology & Medicine* 1986, 2:339-347.
31. Hussain SP, Raja K, Amstad PA et al.: Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. *Proceedings of the National Academy of Sciences of the United States of America* 2000, 97:12770-12775.

32. Seitz HK, Stickel F: Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. *Biological Chemistry* 2006, 387:349-360.
33. Lee KS, Buck M, Houglum K, Chojkier M: Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myc expression. *The Journal of Clinical Investigation* 1995, 96:2461-2468.
34. Fausto N, Campbell JS, Riehle KJ: Liver regeneration. *Hepatology* 2006, 43:S45-53.
35. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK: Oval cell numbers in human chronic liver diseases are directly related to disease severity. *The American Journal of Pathology* 1999, 154:537-541.
36. Ruddell RG, Knight B, Tirnitz-Parker JE et al.: Lymphotoxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. *Hepatology* 2009, 49:227-239.
37. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR: Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. *Hepatology* 2005, 41:809-818.
38. Feng D, Kong X, Weng H et al.: Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. *Gastroenterology* 2012, 143:188-198 e187.
39. Roskams T, Yang SQ, Koteish A et al.: Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. *The American Journal of Pathology* 2003, 163:1301-1311.
40. Smith PG, Yeoh GC: Chronic iron overload in rats induces oval cells in the liver. *The American Journal of Pathology* 1996, 149:389-398.
41. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR: Measurements of iron status in patients with chronic hepatitis. *Gastroenterology* 1992, 102:2108-2113.
42. Trinder D, Ayonrinde OT, Olynyk JK: HCV, iron, and oxidative stress: the new choreography of hepcidin. *Gastroenterology* 2008, 134:348-351.
43. Britton R. S. EJE, Grisham M. B. et al.: Hepatic DNA damage in rats with chronic dietary iron overload. In: *Proceedings of the Third International Conference on Haemochromatosis*. In: *Third International Conference on Haemochromatosis: 1991; 1991*.
44. Nordenson I, Ritter B, Beckman A, Beckman L: Idiopathic hemochromatosis and chromosomal damage. *Human Heredity* 1992, 42:143-145.
45. Farinati F, Cardin R, De Maria N et al.: Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. *Journal of Hepatology* 1995, 22:449-456.
46. Furutani T, Hino K, Okuda M et al.: Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. *Gastroenterology* 2006, 130:2087-2098.
47. Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G: Suppressive effect of ferritin on in vitro lymphocyte function. *British journal of Haematology* 1979, 42:345-353.
48. Olynyk JK, Clarke SL: Iron overload impairs pro-inflammatory cytokine responses by Kupffer cells. *Journal of Gastroenterology and Hepatology* 2001, 16:438-444.

49. Van Thiel DH, Friedlander L et al.: Response to interferon alpha therapy is influenced by the iron content of the liver. *Journal of Hepatology* 1994, 20:410-415.
50. Boucher E, Bourienne A, Adams P et al.: Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. *Gut* 1997, 41:115-120.
51. Olynyk JK, Reddy KR, Di Bisceglie et al.: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology* 1995, 108:1104-1109.
52. Riggio O, Montagnese F, Fiore et al.: Iron overload in patients with chronic viral hepatitis: how common is it? *The American Journal of Gastroenterology* 1997, 92:1298-1301.
53. Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M: Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. *The American Journal of Gastroenterology* 1996, 91:1367-1373.
54. Pianko S, McHutchison JG, Gordon SC et al.: Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. *Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research* 2002, 22:483-489.
55. Lange CM, Kutalik Z, Morikawa K et al.: Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. *Hepatology* 2012, 55:1038-1047.
- 56. Ferrara F, Ventura P, Vegetti A et al.: Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. *The American Journal of Gastroenterology* 2009, 104:605-616.
This article highlights the importance of iron and role in hepatitis C related liver disease. A significant rise in ferriitin during treatment is an independent predictor of therapeutic response.
57. Ryan JD, Altamura S, Devitt E et al.: Pegylated interferon-alpha induced hypoferrremia is associated with the immediate response to treatment in hepatitis C. *Hepatology* 2012, 56:492-500.
58. Dalgard O, Bjoro K, Ring-Larsen H et al.: Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology* 2008, 47:35-42.
59. Fong TL, Han SH, Tsai NC et al.: A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. *Journal of Hepatology* 1998, 28:369-374.
60. Rulyak SJ, Eng SC, Patel K et al.: Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. *The American Journal of Gastroenterology* 2005, 100:332-337.
61. Clemente MG, Congia M, Lai ME et al.: Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. *The Journal of Pediatrics* 1994, 125:123-128.
62. Kato J, Miyanishi K, Kobune M et al.: Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. *Journal of Gastroenterology* 2007, 42:830-836.

63. Van Thiel DH, Friedlander L, Molloy PJ et al.: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. *Hepato-Gastroenterology* 1996, 43:1557-1561.
- 64. Gentile I, Viola C, Paesano L et al.: Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. *Journal of Clinical Apheresis* 2009, 24:190-196.
Phlebotomy prior to combined therapy (pegylated interferon and ribavirin) for hepatitis C showed no increase in efficacy of antiviral therapy. However within the small number of treatment naïve patients there was a strong trend to a higher SVR.
65. Mandayam S, Jamal MM, Morgan TR: Epidemiology of alcoholic liver disease. *Seminars in Liver Disease* 2004, 24:217-232.
66. Milman N, Graudal N, Hegnhøj J, Christoffersen P, Pedersen NS: Relationships among serum iron status markers, chemical and histochemical liver iron content in 117 patients with alcoholic and non-alcoholic hepatic disease. *Hepato-Gastroenterology* 1994, 41:20-24.
67. Olynyk J, Hall P, Reed W et al.: A long-term study of the interaction between iron and alcohol in an animal model of iron overload. *Journal of Hepatology* 1995, 22:671-676.
68. Tsukamoto H, Horne W, Kamimura S et al.: Experimental liver cirrhosis induced by alcohol and iron. *The Journal of Clinical Investigation* 1995, 96:620-630.
69. Harrison-Findik DD, Klein E, Crist C et al.: Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. *Hepatology* 2007, 46:1979-1985.
70. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH: Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. *Gastroenterology* 2002, 122:281-289.
71. Day CP, James OF: Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998, 114:842-845.
72. Farrell GC, van Rooyen D, Gan L, Chitturi S: NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. *Gut and Liver* 2012, 6:149-171.
73. Reid AE: Nonalcoholic steatohepatitis. *Gastroenterology* 2001, 121(3):710-723.
74. Nelson JE, Klintworth H, Kowdley KV: Iron metabolism in Nonalcoholic Fatty Liver Disease. *Current gastroenterology reports* 2012, 14:8-16.
75. Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999, 30:1356-1362.
- 76. Kowdley KV, Belt P, Wilson LA et al.: Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology* 2012, 55:77-85.
This study demonstrates that serum ferritin levels greater than 1.5 times the upper limit of normal in patients with NAFLD is an independent risk factor of advanced fibrosis and further implicates the role of iron in as a second factor worsening liver disease.
77. Sorrentino P, D'Angelo S, Ferbo U et al.: Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. *Journal of Hepatology* 2009, 50:351-357.

78. Valenti L, Moscatiello S, Vanni E et al: Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. *QJM : Monthly Journal of the Association of Physicians* 2011, 104:141-149.
79. Angulo P: Nonalcoholic fatty liver disease. *The New England Journal of Medicine* 2002, 346:1221-1231.
80. Ryan Caballes F, Sendi H, Bonkovsky HL: Hepatitis C, porphyria cutanea tarda and liver iron: an update. *Liver international : Official Journal of the International Association for the Study of the Liver* 2012, 32:880-893.
81. Bonkovsky HL, Lambrecht, R. W.: Hemochromatosis, iron overload, and porphyria cutanea tarda. In: *Hemochromatosis-Genetics, Pathophysiology,Diagnosis and Treatment*. Edited by Barton J. C. ECQ, vol. 2nd ed. Cambridge, UK: Cambridge University Press; 2000: 453–467.
82. Gorman N, Zaharia A, Trask HS et al.: Effect of an oral iron chelator or iron-deficient diets on uroporphyrin in a murine model of porphyria cutanea tarda. *Hepatology* 2007, 46:1927-1834.
83. Epstein JH, Redeker AG: Porphyria cutanea tarda. A study of the effect of phlebotomy. *The New England Journal of Medicine* 1968, 279:1301-1304.
84. Ratnaik S, Blake D, Campbell D, Cowen P, Varigos G: Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. *The Australasian Journal of Dermatology* 1988, 29:3-8.
85. Rocchi E, Gibertini P, Cassanelli M et al.: Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. *The Journal of Laboratory and Clinical Medicine* 1986, 107:36-42.
86. Sarkany RP: The management of porphyria cutanea tarda. *Clinical and Experimental Dermatology* 2001, 26:225-232.
87. Fernandez-Real JM, Lopez-Bermejo A, Ricart W: Cross-talk between iron metabolism and diabetes. *Diabetes* 2002, 51:2348-2354.
88. Dinneen SF, O'Mahony MS, O'Brien T et al.: Serum ferritin in newly diagnosed and poorly controlled diabetes mellitus. *Irish Journal of Medical Science* 1992, 161:636-638.
89. Minamiyama Y, Takemura S, Kodai S et al.: Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. *American Journal of Physiology Endocrinology and Metabolism* 2010, 298:E1140-1149.
90. Houshyar KS, Ludtke R, Dobos GJ et al.: Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. *BMC Medicine* 2012, 10:54.
91. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L: Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. *Journal of Hepatology* 2011, 55:920-932.
92. Valenti L, Swinkels DW, Burdick L et al.: Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. *Nutrition, Metabolism, and Cardiovascular Diseases : NMCD* 2011, 21:568-575.
93. Sung KC, Kang SM, Cho EJ et al.: Ferritin is independently associated with the presence of coronary artery calcium in 12 033 men. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2012, 32(10):2525-2530.
94. Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC: Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. *American Journal of Epidemiology* 2003, 158(2):144-149.

95. Van der A, Rovers MM, Grobbee DE et al.: Mutations in the HFE gene and cardiovascular disease risk: an individual patient data meta-analysis of 53 880 subjects. *Circulation Cardiovascular Genetics* 2008, 1(1):43-50.
96. Kim KS, Son HG, Hong NS, Lee DH: Associations of serum ferritin and transferrin % saturation with all-cause, cancer, and cardiovascular disease mortality: Third National Health and Nutrition Examination Survey follow-up study. *Journal of Preventive Medicine and Public Health = Yebang Uihakhoe chi* 2012, 45(3):196-203.
97. Turlin B, Juguet F, Moirand R et al.: Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. *Hepatology* 1995, 22(2):446-450.
98. Tirmitz-Parker JE, Yeoh GC, Olynyk JK: Liver progenitor cells, cancer stem cells and hepatocellular carcinoma. In: *Liver Regeneration*. Edited by P. B: Intech; 2012: 17-42.
99. Osborne NJ, Gurrin LC, Allen KJ et al.: HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. *Hepatology* 2010, 51(4):1311-1318.
100. Edgren G, Reilly M, Hjalgrim H et al.: Donation frequency, iron loss, and risk of cancer among blood donors. *Journal of the National Cancer Institute* 2008, 100(8):572-579.